News

The CANTOS findings have strengthened the relationship between cardiovascular disease and inflammation. Here’s how they are changing the way clinicians understand heart conditions.

Those who tweet under the hashtag offer up free advice that can cost thousands of dollars elsewhere, either through CME credits or in medical school.

Several studies point to the links between prenatal exposure to painkillers and increased risks for ADHD and autism symptoms.

Treated with Medtronic’s Symplicity Spyral renal denervation system, those patients experienced no major adverse safety events at 6 months.

Congress has voted to pass the Right to Try bill which will provide terminally ill patients with the ability to seek out experimental therapies not yet approved by the FDA.

Two early-stage studies of gene therapies from Pfizer, Spark Therapeutics, and BioMarin Pharmaceutical indicate efficacy for hemophilia A and B treatment.

Study results show that OHTN may be an early biomarker of hypertension and may herald risk of developing AMD, and perhaps, other conditions caused by vascular disease.

The study estimated that full achievement of the 2017 hypertension guidelines would prevent 610,000 major cardiovascular events and 334,000 deaths in the US annually.

Survey results from the IPA/Erasmus MC Pompe survey investigated whether ERT can reduce Pompe disease patients’ risk of needing either a wheelchair, respirator, or both.

Results from an online, self-administered survey showed a mostly consistent and unified response in pulmonologist treatment responses.

An analysis of over 1,200 patients from pivotal studies finds that Esbriet helped blunt seasonal peaks in respiratory hospitalizations among patients with idiopathic pulmonary fibrosis.

Diabetes causes ELOVL4 to be downregulated, weakening the tight junctions. Researchers hope that replacing these lipids could be a treatment for diabetic retinopathy.

Avinger stated that it plans to incorporate this next generation version of the device into its ongoing clinical trial program, INSIGHT, an FDA Investigation Device Exemption study.

The bill will now head to President Donald Trump for final approval, which will likely be the case, as the president has repeatedly supported the potential new law, most recently in his 2018 State of the Union address.

Supported by positive data from an ongoing Phase 2/3 study, bluebird bio’s Lenti-D has been granted Breakthrough Therapy designation by the US FDA for the treatment of patients with cerebral adrenoleukodystrophy.

Within 6 months, clinicians with access to the test results were 1.44 times more likely to have diagnosed or excluded ADHD.

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.

New data presented yesterday at the American Thoracic Society’s 2018 annual conference suggest that treatment with nintedanib (Ofev) is associated with a reduced risk of death in patients with idiopathic pulmonary fibrosis.

From 2000 to 2016, the proportion of organ donors who died of drug intoxication increased from 1.2% to 13.7% in the US.

The oral dual inhibitor is intended to work alongside insulin therapy to improve blood sugar control in adults with type 1 diabetes.

Yesterday, UroGen Pharma Ltd released positive data from its interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel) for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).

Results from a recent head-to-head pharmacokinetic study show Rebinyn is more effective than rFIXFc in adults with hemophilia B.

The U.S. FDA has completed their Priority Review and granted full approval to avatrombopag (Doptelet) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

The lifetime risks for a female with only amyloidosis are 8.4% for a 90-year-old and 29.3% for a 65-year-old, but persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%.

This is the fifth indication approved for Amgen’s Prolia (denosumab), which targets RANK Ligand, an essential regulator of osteoclasts.

Results from Roche's phase III HAVEN 3 and phase III HAVEN 4 studies, which assessed the administration of Hemlibra (emicizumab) in people with hemophilia A without factor VIII inhibitors, show efficacy.

NORD's Voice of the Community - May 2018

New data demonstrates clinical benefit in hemophilia B patients with pre-existing anti-AAV5 neutralizing antibodies.

FlowTriever is the first thrombectomy device cleared for the treatment of pulmonary embolism.

Burosumab (Crysvita) was approved by the US FDA to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare genetic variation of rickets. Phase 3 study results help explain why.